EMCC European Monitoring Centre on Change



Geographic Location

Country: Germany
Region: Rostock, Kreisfreie Stadt; Mecklenburg-Vorpommern
Location of affected unit(s): Rostock


Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Number Employed: 530

Employment Effects

Announcement Date: 24-11-2021
Planned Job Reductions min: 80
Planned Job Reductions max: 80
Type of Restructuring: Internal restructuring
Employment Effect Start: 01-01-2022
Foreseen End Date: 31-03-2022
Other Job Reduction Measures: 80

Additional Information

Centogene, a German company specialised in diagnostics and research of rare diseases, will be cutting approximately 80 jobs at its site in Rostock. According to the company’s third quarter report, Centogene will phase out its non-core COVID-19 testing services by early 2022 (no exact date available) which will result in the loss of 80 employees out of the 530 people currently employed at the Rostock site.

As of now, there is no information on a social plan available.

Centogene is a global biotechnology company founded in Rostock, Germany with further offices in Germany as well as in US.